Ecco 16 - esmo36

Congress Update Service, Issue for August 2011
2011 European Multidisciplinary Cancer Congress: Spotlight on
22 days and counting until the largest European Multidisciplinary Cancer Congress takes place in Stockholm! 262 Scientific Committee members have jointly compiled an outstanding 33-Track programme containing the latest developments in cancer research, treatment and care. This meeting provides a unique platform for all professionals with a common interest in oncology to discuss, debate and deliberate new data.
285 sessions host over 2,000 presentations from 707 eminent experts containing their latest data, knowledge and experience. The programme has attracted a record number of late-breaking abstracts, presenting practice-changing data in four presidential sessions and 25 proffered paper sessions. A must attend for all! If you have yet to register, avail of our 20% discount on the late rate registration fee to members of one of ECCO’s member societies only (875 instead of 1,095 EUR. This offer is not applicable to nursing, student and patient advocate rates).
Hot New Data -
Hot New Data -
Pick of the
ECCO16 - ESMO36 -
file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] Hot New Data - not to be missed!
Presidential sessions: Late-Breaking and Best Abstracts Saturday 24 September 2011, 13:45 - 15:35
Presidential Session I: Best and Late-Breaking Abstracts
Best Abstract: A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients with Advanced L. Dirix, M.R. Migden, A.E. Oro, A. Hauschild, K. Lewis, A.B. Mueller, R. Yauch, J.C. Reddy, A. Sekulic: Late-Breaking Abstract: Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III C. Parker, D. Heinrich, J.M. O'Sullivan, S. Fosså, A. Chodacki, T. Demkow, A. Cross7, B. Bolstad, J. Garcia-Vargas, O. Sartor: Late-Breaking Abstract: Very Accelerated Radiotherapy (RT) Versus Concomitant Chemo-Radiotherapy (Ct-Rt) In Locally Advanced Head and Neck Cancer: Long Term Results from 2 Phases III GORTEC Randomised J. Bourhis, C. Sire, P. Graff, V. Grégoire, P. Maingon, M. Lapeyre, J.C.G. Tortochaux, B. Gery, L. Martin, M. Alfonsi, P. Deprez, T. Pignon, E. Bardet, M. Rives, A. Pinna, M. Ducoutieux, A. Aupérin: Late-Breaking Abstract: Everolimus in Subependymal Giant Cell Astrocytomas (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Results of EXIST-1, a Double-Blind Placebo-controlled Phase 3 Trial M. Bebin, D.N. Franz, T. Sahmoud, E. Belousova, S. Sparagana, M. 4LBA Frost, J. Ford, G. Shah, H. Cauwel, S. Jozwiak: Sunday 25 September, 12:20 - 14:40
Presidential Session II: Best and Late-Breaking Abstracts
Best Abstract: Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] 84214355) Presented on Behalf of the SECRAB Steering Committee I. Fernando, S.J. Bowden, C.L. Brookes, R. Grieve, D. Spooner, R.K. Agrawal, A.M. Brunt, M. Churn, D.W. Rea, P. Canney: Late-Breaking Abstract: Results from VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal J. Tabernero, E. Van Cutsem, R. Lakomy, J. Prausova, P. Ruff, G. Van Hazel, V. Moiseyenko, D. Ferry, J. McKendrick, K. Soussan- Late-Breaking Abstract: Efficacy in Patient Subgroups in OCEANS, a Randomized, Double-blinded, Placebo-controlled, Phase 3 Trial of Chemotherapy ± Bevacizumab in Patients with Platinum-sensitive Recurrent Epithelial Ovarian (OC), Primary Peritoneal (PPC), or Fallopian Tube Cancer C. Aghajanian, S.V. Blank, B. Goff, P.L. Judson, S. Makhija, S.K. Sharma, L.R. Nycum, J. Yi, A. Husain: Late-Breaking Abstract: A Multicentre Randomised Trial of Ibandronate Compared to Single Dose Radiotherapy for Localised Metastatic Bone Pain P. Hoskin, S. Sundar, K. Reczko, S. Forsyth, N. Mithal, B. Sizer, L. Monday 26 September, 12:15 - 14:25
Presidential Session III: Best and Late-Breaking
Late-Breaking Abstract: Delivering Affordable Cancer Care in High-income R. Sullivan, J. Peppercorn, K. Sikora, J. Zalcberg, N. Meropol, E. Amir, D. Khayat, P. Boyle, I. Tannock, T. Fojo: Best Abstract: VANTAGE 014: Vorinostat in Patients With Advanced Malignant Pleural Mesothelioma (MPM) Previously Treated With Pemetrexed and Either Cisplatin or Carboplatin Therapy: a Phase III, Randomized, L.M. Krug, H.L. Kindler, H. Calvert, C. Manegold, A.S. Tsao, D. Fennell G.M. Lubiniecki, X. Sun, M.M. Smith, P. Baas: Late-Breaking Abstract: Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results Of the BOLERO-2 Phase III Trial J. Baselga, M. Campone, T. Sahmoud, M. Piccart, H. Burris, H. Rugo, S. Noguchi, M. Gnant, P. Mukhopadhyay, G. Hortobagyi: Late-Breaking Abstract: The EORTC 10041/BIG 03-04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics M. Piccart, J. Bogaerts, F. Cardoso, G. Werutsky, S. Delaloge, L. file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] Van 't Veer6, I. Rubio7, C. Moulin8, K. Engelen9, G. Viale10, A.M. Thompson, R. Passalacqua, U. Nitz, P. Vuylsteke, J.Y. Pierga, E. Late-Breaking Abstract: Laparoscopic Surgery Versus Open Surgery for Rectal Cancer: Short-term Outcomes of a Randomised Trial H.J. Bonjer, E. Haglind, M.A. Cuesta, A. Fürst, A. Lacy, M.H.G.M. van der Pas, W.C.J. Hop, The COLOR II Study Group:A Hot New Data - Part Two
Late Breaking Abstracts in Proffered Paper sessions Saturday 24 September 2011
Proffered Papers Session: Gastrointestinal Malignancies -
Colorectal Cancer, 11:15 - 13:50
Late-Breaking Abstract:A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC), the RESPECT Trial J. Tabernero, R. Garcia-Carbonero, C.H. Köhne, P.J. O'Dwyer, A. Sobrero, E. Van Cutsem, O. Gladkov, I. Davidenko, R. Salazar, J. Proffered Papers Session: Lung Cancer-Metastatic, 11:15
Late-Breaking Abstract: A Phase II Study of Sorafenib in Patients with Locally Advanced And/or Metastatic (stage IIIB or IV) Non-small Cell Lung A.M. Dingemans, W.W. Mellema, H.J.M. Groen, A. van Wijk, S. Burgers, P.W.A. Kunst, F.B. Thunnissen, D.A.M. Heideman, E.F. Late-Breaking Abstract: AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev+Pemetrexed (pem) After First-line (1L) Bev- F. Barlesi, J. de Castro, V. Dvornichenko, J.H. Kim, A. Pazzola, A. Rittmeyer, A. Vikström, L. Mitchell, E.K. Wong, V. Gorbunova: Proffered Papers Session: Head and Neck Cancer, 11:15 -
Late-Breaking Abstract: Safety and Efficacy of Panitumumab (pmab) in HPV Positive (+) and HPV Negative (-) Recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of the Phase 3 file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] J. Vermorken, J. Stöhlmacher, K. Oliner, C. Villanueva, P. Foa, E. Winquist, L. Licitra, K. Skladowski, Z. Pan, B.A. Bach: Proffered Papers Session: Melanoma and Skin Cancer,
11:15 - 13:15
Late-Breaking Abstract: Vemurafenib Improves Overall Survival Compared to Dacarbazine in Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multicentre Trial G. McArthur, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, R.J. Lee, K. Nolop, B. Nelson, K.T. Flaherty, P.B. Chapman: Sunday 25 September 2011
Proffered Papers Session: Breast Cancer - Advanced
Disease, 09:00 - 11:35
Late-Breaking Abstract: Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast G.S. Bhattacharyya, J. Biswas, J.K. Singh, M. Singh, K. Govindbabu, A.A. Ranade, H. Malhotra, P.M. Parikh, T. Shahid, S. Late-Breaking Abstract:A Double-blind, Randomized Phase IIb Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial G. Mariani, O. Burdaeva, L. Roman, E. Staroslawska, D. Udovitsa, P. Driol, G. Goisis, C. Zamagni, V. Semiglazov, L. Gianni: Proffered Papers Session: Personalised Medicine, 09:00 -
Late-Breaking Abstract: Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC) M. Peeters, J.Y. Douillard, E. Van Cutsem, S. Siena, K. Zhang, R. Proffered Papers Session: Lung Cancer-Localised/Local
Regional, 09:00 - 10:30
Late-Breaking Abstract: Results of a Pilot External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non-Small Cell Lung Cancer N. Normanno, S. Patton, S. Murray, F. Blackhall, K.M. Kerr, M. Dietel, M. Filipits, M. Taron, R. Stahel, E. Thunnissen: Proffered Papers Session: Genitourinary Malignancies -
Prostate Cancer, 09:00 - 11:00
Late-Breaking Abstract: Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08), On Behalf of the file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] N.D. James, M.R. Sydes, M.D. Mason, N.W. Clarke, D.P. Dearnaley, J. Dwyer, G. Jovic, J.M. Russell, G. Thalmann, M.K.B. Late-Breaking Abstract: Escalated-dose Conformal Radiotherapy for Localised Prostate Cancer: Long-term Overall Survival Results From the MRC RT01 Randomised Controlled Trial, On Behalf of the RT01 D.P. Dearnaley, G. Jovic, I. Syndikus, J.D. Graham, E.G. Aird, V. Proffered Papers Session: Central Nervous System, 09:00
Late-Breaking Abstract: Clinical, Molecular, and Molecular-Clinical Profile (MCP) Exploratory Subset Analysis of RTOG 0525: a Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense M. Mehta, M. Wang, K. Aldape, E. Sulman, R. Stupp, K. Jaeckle, D. 18LBA Blumenthal, S. Erridge, W. Curran, M. Gilbert): Monday 26 September 2011
Proffered Papers Session: Gynaecological Cancer, 09:00 -
Late-Breaking Abstract: Quality of Life Outcomes of a Randomized, Placebo- Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: a Gynecologic Oncology Group Study B.J. Monk, H. Huang, R.A. Burger, R.L. Mannel, H.D. Homesley, J. Fowler, B.E. Greer, M. Boente, S.X. Liang, L. Wenzel: Late-Breaking Abstract: Quality of Life in the ICON7 GCIG Phase III D. Stark, M. Nankivell, F. Hilpert, L. Elit, J. Brown, A. Lanceley, G. Valikova, A. Oza, A.M. Swart, T. Perren: Late-Breaking Abstract: Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum H. Gungor, E. Stronach, E. Curry, A. Saleem, R. Agarwal, S. Blagden, S. Babar, G. Mills, S.R. Morris, H. Gabra: Oncology Nursing
Proffered Papers Session: Nursing - Supportive Care,
09:00 - 11:15
Late-Breaking Abstract: Unrecognised and Underprepared: an Exploratory Mixed Method Study of Informal Carers’ Experiences of Supporting E. Ream, V. Pedersen, C. Oakley, A. Richardson, C. Taylor, R. file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] Proffered Papers Session: Basic Science/Translational
Research, 14:45 - 17:10
Late-Breaking Abstract: Drugging the Undruggable: Small-molecule Inhibition
G. Fang, T. Maurer, L. Garrenton, N. Skelton, B. Fauber, S. Malek, 15LBA A. Giannetti, P. Jackson, J. Rudolph, W. Wang: Tuesday 27 September 2011
Proffered Papers Session: Sarcoma, 09:00 - 11:30
Late-Breaking Abstract: A Randomized Clinical Trial of Adjuvant Chemotherapy with Doxorubicin, Ifosfamide, and Cisplatin in Localized Uterine Sarcomas. Results on 81 Randomized Patients P. Pautier, A. Floquet, L. Gladieff, D. Berton-Rigaud, S. Piperno- Neumann, F. Selle, I. Ray-Coquard, C. Guillemet, B. Weber, A. Late-Breaking Abstract: Denosumab Treatment for Giant Cell Tumour of Bone (GCTB) in Adolescent Patients: Interim Results From a Phase 2 Study J. Engellau, S. Chawla, R. Grimer, A. Powell, S. Schuetze, K. Skubitz, A. Staddon, C. Atchison, Y. Zhao, I. Jacobs: Late-Breaking Abstract: Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population P. Reichardt, J.T. Hartmann, K. Sundby Hall, M. Eriksson, J. Schütte, G. Ramadori, P. Hohenberger, J. Duyster, M. Leinonen, H. 31LBAJoensuu: Pick of the Programme
Proffered Paper Session on Personalised Medicine, Sunday
25 September, 09:00-10:50
Biomarkers are becoming more important in determining effectiveness of treatment response. This session highlights the latest data in detecting novel mutations in NSCLC, colorectal cancer and melanoma. Featuring studies on evaluating plasma VEGFA as potential biomarker following treatment of Bevacizumab, it also includes a study on using dynamic contrast-enhanced ultrasound (DCE-US) as an effective tool to evaluate antiangiogenic Special Session on MIRACLE Workshop: Novel
Technologies for the Isolation and Analysis of Circulating
Tumour Cells, 14:45-16:45
Circulating tumour cells (CTC) and disseminating tumour cells (DTC) are cells detached from the primary tumour, acting as seeds for tumour growth on other sites and are very important predictive and prognostic markers for the file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] treatment of advanced cancer. However, with very low levels of CTCs in the blood, they are difficult to detect and isolate.
One of two special sessions, the MIRACLE workshop will discuss development of novel technologies to detect CTCs and issues and hurdles to be overcome to produce highly sophisticated devices to detect minute quantities of CTCs and DTCs in the blood and bone marrow. Leading experts in bioengineering and nanotechnology, Leo Terstappen, Philip Gascoyne, Chiwee Teck Lee and Lisbet Lagae will discuss and address these issues.
MIRACLE is a collaborative project between 14 partners from universities, research institutions and companies from all over Europe. The term MIRACLE is an acronym of the projects title ‘Magnetic Isolation and moleculaR
Analysis of single CircuLating and disseminated tumour cElls on chip’. The
project is funded by the European Commission within the 7th Framework
Special Session on Circulating Tumour Cells, Monday 26
September, 13.15-14.15
This session will present the use of CTCs in the clinic and existing technologies for detecting CTCs and their markers.
Klaus Plantel will discuss the reasons for monitoring CTCs during and after systemic adjuvant therapy. Stefan Sleijfer will present the importance of CTC enumeration and characterisation. Caroline Dive will discuss the technological This session also features a highly interactive discussion on how the detection Special Session on Stem Cells, Sunday 25 September,
Stem cells are core cells that can divide and differentiate into different types of specialised cells, and can self renew in more cells. Stem cell research has been performed across multiple diseases, most notably Parkinson’s disease. This session will cover cancer stem cells in different tumour types. Rune Toftgard will discuss stem cells in skin cancer. Per Giuseppe Pelicci will talk about haematopoietic stem cells and Simone Niclou will consider cancer stem Each presentation will highlight the importance of cancer stems cells in the survival of the tumour and the implications to future cancer treatments.
Official Media Partners:
You have been sent this email because you have subscribed online at file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42] to receive this Congress Update Service, or have attended or expressed an interest in an ECCO event in the past. If you do not wish to continue to receive this special Update Service, please forward this message to the file:///C|/Users/nicola.FECS/Desktop/Issue7_August2011_rev3.htm[07/10/2011 15:05:42]


Counterfeit and adulterated prescription drugs | attention-de.

Counterfeit and Adulterated Prescription Drugs | Attention-Deficit/Hype. Pharmacy Times - Attention-Deficit/Hyperactivity Disorder Normal Version Counterfeit and Adulterated Prescription Drugs Several years ago, I attended the annual conference of the National Association of Drug Diversion Investigators (NADDI) in

DIÁRIO DA REPÚBLICA — I SÉRIE-A Como previsto na Lei de Bases da Saúde, o controloNo desenvolvimento do regime jurídico estabelecidode qualidade de toda a prestação de cuidados de saúdepela Lei n.o 11/89, de 1 de Junho, e nos termos dadeve estar sujeito ao mesmo nível de exigência. alínea c ) do n.o 1 do artigo 198.o da Constituição, oForam ouvidas a Ordem dos Médicos, a O

Copyright © 2014 Medical Pdf Articles